Treatment & Research
A Mesothelioma Drug Attacks the Tumor's Own Stress Defenses. Here's What Its First Trial Actually Found
RSO-021 controlled disease in 6 of 9 evaluable people at 12 weeks in a phase 1 trial. The full results, and what they don't yet show.